Skip to main
GRDN
GRDN logo

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. is positioned positively due to its strong technological capabilities that enhance value-based care discussions and improve operational efficiencies, particularly following the integration of its technology platforms into newly acquired operations. The company benefits from a significant market share across its pharmacy segments, coupled with a robust tech stack that serves as a competitive differentiator, allowing for attractive earnings potential from recent acquisitions. Additionally, the utilization of approximately 80 robotic dispensing machines has optimized operational accuracy and efficiency, reducing the time to fulfill requisitions to under one day, which further enhances the company's service delivery in the long-term care facility market.

Bears say

Guardian Pharmacy Services Inc is facing multiple risks that contribute to a negative outlook for its stock. Key concerns include potential regulatory and reimbursement changes, challenges in managing relationships with long-term care facilities (LTCFs), and disruptions in the supply chain. Additionally, the company's reliance on technology assets, along with difficulties in hiring and retaining clinical staff and integrating acquisitions, further exacerbate the uncertainty surrounding its financial stability and growth.

GRDN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 2 analysts, GRDN has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.